Fund Holdings — Sarissa Capital Management LP

Total Portfolio Value
$402.33M
Total Bought
$2.85M
Total Sold
$162.30M
Net Transaction
-$159.44M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q2 2024
▲▼
Q3 2024
▲▼
Change
▲▼
Q2 2024
▲▼
Q3 2024
▲▼
Weight (%)
▲▼
Change
▲▼
INNOVIVA INC(INVA)7,277,0007,277,0000119,343140,51934.93%+21,176
LANTHEUS HLDGS INC(LNTH)026,000+26,00002,8540.71%+2,854
REGULUS THERAPEUTICS INC185,183185,18303312910.07%-40
VOR BIOPHARMA INC(VOR)618,000618,00006184330.11%-185
AMARIN CORP PLC24,850,62324,850,623017,09715,5793.87%-1,518
CYTOKINETICS INC(CYTK)1,110,0001,110,000060,14058,60814.57%-1,532
BIOCRYST PHARMACEUTICALS INC(BCRX)1,094,1680-1,094,1686,7620—-6,762
NEUROCRINE BIOSCIENCES INC(NBIX)410,483410,483056,51147,29611.76%-9,215
GILEAD SCIENCES INC(GILD)1,103,282763,333-339,94975,69663,99815.91%-11,698
IRONWOOD PHARMACEUTICALS INC(IRWD)16,390,00016,390,0000106,86367,52716.78%-39,336
BIOGEN INC(BIIB)643,00026,950-616,050149,0605,2241.30%-143,836
Page 1 of 1
Sarissa Capital Management LP — 13F Holdings — Q3 2024 | TickerTrail